Sign in to view content

Open-Label Study Evaluating the Effects of the CCR3 Antagonist ALK4290 in Patients With Neovascular AMD Refractory to Anti-VEGF Therapy

Michael W. Stewart, MD

Video
Published 2019

Michael W. Stewart, MD

AMD Neovascular Part II Symposium

Related

Two-Year Results of an Ongoing Phase 1b/2 Open-Label Clinical Trial of AU-011 for the Primary Treatment of Small to Medium Choroidal Melanoma
Amy C. Schefler, MD FACS FASRS
Annual Meeting Talks
2019
Severe Vision Loss After Intravitreal Injections of Autologous Adipose Tissue-derived Stem Cells for Age-Related Macular
Ajay E Kuriyan, MD, MS
Updates from the Field
2016
BiWeekly Anti-VEGF Dosing for Chronic Refractory Neovascular Age-Related Macular Degeneration Unresponsive to Standard Monthly Dosing
Eric W Schneider, MD
Annual Meeting Talks
2019

Category: AMD-Neovascular

See more